Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Johnson and Johnson
Medtronic
Moodys

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Vilaprisan

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Vilaprisan: Sponsors, patents, clinical trial progress

Vilaprisan is an investigational drug.

There have been 15 clinical trials for Vilaprisan. The most recent clinical trial was a Phase 2 trial, which was initiated on June 30th 2017.

The most common disease conditions in clinical trials are Leiomyoma, Myofibroma, and Endometriosis. The leading clinical trial sponsors are Bayer and [disabled in preview].

There are three US patents protecting this investigational drug and seventy-four international patents.

Recent Clinical Trials for Vilaprisan
TitleSponsorPhase
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine FibroidsBayerPhase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With EndometriosisBayerPhase 2
A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual BleedingBayerPhase 3

See all Vilaprisan clinical trials

Clinical Trial Summary for Vilaprisan

Top disease conditions for Vilaprisan
Top clinical trial sponsors for Vilaprisan

See all Vilaprisan clinical trials

US Patents for Vilaprisan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vilaprisan   Start Trial 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)   Start Trial
Vilaprisan   Start Trial 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases Bayer Pharma Aktiengesellschaft (Berlin, DE)   Start Trial
Vilaprisan   Start Trial 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vilaprisan

Drugname Country Document Number Estimated Expiration Related US Patent
Vilaprisan Argentina 077491 2029-07-20   Start Trial
Vilaprisan Australia 2010275849 2029-07-20   Start Trial
Vilaprisan Brazil 112012001344 2029-07-20   Start Trial
Vilaprisan Canada 2768407 2029-07-20   Start Trial
Vilaprisan China 102482317 2029-07-20   Start Trial
Vilaprisan Colombia 6491067 2029-07-20   Start Trial
Vilaprisan Costa Rica 20120040 2029-07-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Baxter
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.